User profiles for C. M. Lourenco
Charles Marques LourençoUniversity of Sao Paulo Verified email at usp.br Cited by 12325 |
Recommendations for the detection and diagnosis of Niemann-Pick disease type C: An update
…, HH Klünemann, P Latour, CM Lourenço… - Neurology: Clinical …, 2017 - AAN Enterprises
… CM Lourenco has received speaker honoraria from Actelion, Alexion, and Shire. All fees
are donated to the CML Medical Foundation for Research and Diagnosis Support, helping …
are donated to the CML Medical Foundation for Research and Diagnosis Support, helping …
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature
…, M Kawaguchi, R Kumar, JPSM Lin, CM Lourenco… - Nature …, 2012 - nature.com
Adenosine deaminases acting on RNA (ADARs) catalyze the hydrolytic deamination of
adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the …
adenosine to inosine in double-stranded RNA (dsRNA) and thereby potentially alter the …
Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response
… In order to identify other genes involved in AGS, we conducted a SNP array genome-wide
scan using affected individuals from these four families, and identified a 2-cM region of shared …
scan using affected individuals from these four families, and identified a 2-cM region of shared …
Multi-system neurological disease is common in patients with OPA1 mutations
P Yu-Wai-Man, PG Griffiths, GS Gorman, CM Lourenco… - Brain, 2010 - academic.oup.com
Additional neurological features have recently been described in seven families transmitting
pathogenic mutations in OPA1, the most common cause of autosomal dominant optic …
pathogenic mutations in OPA1, the most common cause of autosomal dominant optic …
[HTML][HTML] Treatment of Fabry's disease with the pharmacologic chaperone migalastat
…, K Nedd, U Sharaf El Din, CM Lourenco… - New england journal …, 2016 - Mass Medical Soc
Background Fabry’s disease, an X-linked disorder of lysosomal α-galactosidase deficiency,
leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic …
leads to substrate accumulation in multiple organs. Migalastat, an oral pharmacologic …
[PDF][PDF] Clinical and molecular phenotype of Aicardi-Goutieres syndrome
…, A Leitch, MJ Lim, JH Livingston, CM Lourenco… - The American Journal of …, 2007 - cell.com
Aicardi-Goutières syndrome (AGS) is a genetic encephalopathy whose clinical features mimic
those of acquired in utero viral infection. AGS exhibits locus heterogeneity, with mutations …
those of acquired in utero viral infection. AGS exhibits locus heterogeneity, with mutations …
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT …
…, E Hachulla, A Jovanovic, CM Lourenco… - Journal of medical …, 2017 - jmg.bmj.com
Background Fabry disease is an X-linked lysosomal storage disorder caused by GLA mutations,
resulting in α-galactosidase (α-Gal) deficiency and accumulation of lysosomal substrates…
resulting in α-galactosidase (α-Gal) deficiency and accumulation of lysosomal substrates…
Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 …
…, JPSM Lin, JH Livingston, CM Lourenco… - The lancet …, 2013 - thelancet.com
Background Aicardi-Goutières syndrome (AGS) is an inflammatory disorder caused by
mutations in any of six genes (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and …
mutations in any of six genes (TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and …
[HTML][HTML] Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
…, A Acosta, C Bonfim, CM Lourenço… - … and molecular biology, 2010 - SciELO Brasil
Mucopolysaccharidoses (MPS) are rare genetic diseases caused by the deficiency of one of
the lysosomal enzymes involved in the glycosaminoglycan (GAG) breakdown pathway. This …
the lysosomal enzymes involved in the glycosaminoglycan (GAG) breakdown pathway. This …
PNPLA6 mutations cause Boucher-Neuhäuser and Gordon Holmes syndromes as part of a broad neurodegenerative spectrum
Boucher-Neuhäuser and Gordon Holmes syndromes are clinical syndromes defined by
early-onset ataxia and hypogonadism plus chorioretinal dystrophy (Boucher-Neuhäuser …
early-onset ataxia and hypogonadism plus chorioretinal dystrophy (Boucher-Neuhäuser …